Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07565-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Adrianna Bilinska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. Hauptthemen laut MEDLINE: Lutetium, Radioisotopes, Theranostic Nanomedicine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE European Research Council.
Abstract (Originalsprache)
Purpose
This study aims to assess DOTAGA.Glu.(FAPI) 2 and DO3A.Glu.(FAPI) 2 , specifically engineered as precursors for the development of theranostic FAPI-targeted radioligands.
Methods
DOTAGA.Glu.(FAPI) 2 and DO3A.Glu.(FAPI) 2 were radiolabeled with gallium-68 and lutetium-177, followed by in vitro (lipophilicity, protein binding, saturation, internalization and externalization) studies on FAP + CAFs. In vivo (biodistribution, metabolic stability, blood kinetics, PET/SPECT/CT imaging) and ex vivo, (autoradiography, immunohistochemistry) conducted on PC3-mice. Murine dosimetry data were extrapolated to human estimates.
Results
All radioligands achievied > 98% radiochemical purity, demonstrating high FAP affinity (K d :0.7–0.9 nM) and rapid internalization in CAFs, with differences in lipophilicity and serum protein binding. In vivo studies, for [ 68 Ga]Ga-DOTAGA.Glu.(FAPI) 2 and [ 68 Ga]Ga-DO3A.Glu.(FAPI) 2 showed high and sustained tumor uptake up to 3 h p.i. (18–19%I.A./g). For [ 177 Lu]Lu-DOTAGA.Glu.(FAPI) 2 and [ 177 Lu]Lu-DO3A.Glu.(FAPI) 2 tumor uptake was 16.2 ± 2.5 and 15 ± 1.2% IA/g at 4 h p.i., reaching 5.1 ± 0.1 and 2.8 ± 0.4%IA/g at 48 h, respectively. All radioligands exhibited low blood retention levels. PET/SPECT/CT imaging confirmed high tumor-to-background ratios. Uptake patterns correlate well with autoradiography images of heterogeneous FAP distribution in PC3-mice, while the detection of both murine and human FAP in PC3-tumors was demonstrated through immunohistochemistry. The extrapolated human absorbed dose estimates (Gy/GBq) for [ 177 Lu]Lu-DOTAGA.Glu.(FAPI) 2 were generally higher across most organs compared to [ 177 Lu]Lu-DO3A.Glu.(FAPI) 2 . Human extrapolation of the 161 Tb-labeled radioligands delivered on average ~ 38% higher absorbed doses in tissues as compared to their 177 Lu-labeled counterparts.
Conclusion
These results support the potential clinical translation of DOTAGA.Glu.(FAPI) 2 and DO3A.Glu.(FAPI) 2 , as promising candidates for precise diagnosis and treatment of FAP-expressing malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
- Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland.
- Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Chemistry-TRIGA site, Johannes Gutenberg-University Mainz, Mainz, Germany.
- Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. eleni.gourni@insel.ch.
ORCID-Profile: Eleni Gourni
Förderung
- HORIZON EUROPE European Research Council
Zitieren
APA
Bilinska, A., Kumar, N., Gnesin, S., Läppchen, T., Menéndez, E., Martin, M., Rösch, F., Rominger, A., & Gourni, E. (2026). Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07565-9
Vancouver
Bilinska A, Kumar N, Gnesin S, Läppchen T, Menéndez E, Martin M, et al. Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07565-9
BibTeX
@article{Bilinska2026,
author = {Bilinska, Adrianna and Kumar, Naveen and Gnesin, Silvano and Läppchen, Tilman and Menéndez, Elena and Martin, Marcel and Rösch, Frank and Rominger, Axel and Gourni, Eleni},
title = {Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07565-9}
}
EUVIMED